Please login to the form below

Not currently logged in
Email:
Password:

Recentin goes into phase three studies

Recentin, AstraZeneca's developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer

Recentin, AstraZeneca's (AZ) developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer.

A phase II review by the Horizon Independent Data Monitoring committee concluded that Recentin had met pre-requisite criteria to move into the next stage of trails.

Colorectal cancer is the third most common from of cancer affecting 945,000 people worldwide, with 492,000 being reported annually.

John Patterson, AZ's executive director for development, said: ìGiven there is such a high unmet patient need for more effective treatments in cancer, we are pleased that the Horizon colorectal cancer programme has met its pre-defined criteria to continue into phase III.

However, the National Cancer Institute of Canada Clinical Trails Group (NCIC-CTG) that Recentin will not be continuing into phase III of their trails of Recentin in non-small cell lung cancer (NSCLC).

Patterson said: "AZ supports the NCIC-CTG's recommendation and is working with them to understand the data more fully in NSCLC."

Recentin is being trailed for use in treatment of glioblastoma, and other tumours.

27th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics